Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis.
Mult Scler Relat Disord
; 52: 102922, 2021 Jul.
Article
in English
| MEDLINE | ID: covidwho-1157623
ABSTRACT
A 32-year-old woman with highly active MS was infected with SARS-CoV-2 while on treatment with rituximab. She recovered and was symptom-free for 21 days before receiving rituximab and IVIg for comorbid hypogammaglobulinemia. Three days after the infusion she redeveloped respiratory symptoms and required admission. Three SARS-CoV-2 nasopharyngeal swabs and antibody testing was negative; however, bronchial alveolar lavage detected SARS-CoV-2. Reactivation of SARS-CoV-2 after rituximab for MS has not been reported but is a known risk in other conditions. The timing of anti-CD20 treatment after SARS-CoV-2 infection requires further investigation and individual consideration to reduce the risk of reactivation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Multiple Sclerosis
Type of study:
Case report
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS